Long-term safety evaluation of ONO-4538 in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to confirm the long-term safety of ONO-4538 in participants with various tumors who are receiving ONO-4538 either alone or in combination with other therapies. Participants must be currently treated with ONO-4538 as part of ongoing clinical trials. The study will monitor the safety profile and any adverse effects associated with the treatment over an extended period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials
2. Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit

Exclusion Criteria:

1. Participant judged to be incapable of providing consent for reasons such as concurrent dementia
2. Participant judged by the investigator to be inappropriate as participants of this study

Where it's running

• Hiroshima Clinical Site1
  Hiroshima, Hiroshima, Japan Recruiting
• Hokkaido Clinical Site1
  Sapporo, Hokkaido, Japan Recruiting
• Kyoto Clinical Site1
  Kyoto, Kyoto, Japan Recruiting
• Oita Clinical Site1
  Yufu, Oita Prefecture, Japan Recruiting
• Okayama Clinical Site1
  Okayama, Okayama-ken, Japan Recruiting
• Osaka Clinical Site2
  Osaka, Osaka, Japan Recruiting

Study contacts

• Study coordinator: North America Clinical Trial Support Desk
• Email: clinical_trial@ono-pharma.com
• Phone: +18665877745(Toll-Free)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing HER2 test results and readings across labs for Chinese patients with NSCLC, gynecologic, biliary tract, or urothelial cancers

  This project will test how well different HER2 lab tests and pathologist readings agree for people in China with NSCLC, certain gynecologic cancers, biliary tract cancer, or urothelial cancer using archived tumor samples.

  Recruiting at 2 sites AstraZeneca · Beijing and 13 other locations · NCT07404202

• Evaluating skin lesions in patients with various types of vasculitis

  This study is testing how skin lesions from different types of vasculitis look under a microscope to help doctors better understand and treat these conditions.

  Recruiting at 4 sites University of Pennsylvania · Los Angeles, California and 9 other locations · NCT03004326

• Registry for women with vasculitis during pregnancy

  This study is gathering information from pregnant women with vasculitis to understand their experiences and health outcomes during and after pregnancy.

  Recruiting University of Pennsylvania · Tampa, Florida · NCT02593565

• Analyzing cancer genetics for better prevention and treatment

  This study is trying to find genetic clues in cancer patients' samples to improve prevention and treatment options for cancer.

  Recruiting at 5 sites Mayo Clinic · Scottsdale, Arizona and 4 other locations · NCT06008392

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.